BioNTech SE Sponsored ADR $BNTX Shares Bought by LRI Investments LLC

LRI Investments LLC boosted its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 234.6% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 445 shares of the company’s stock after acquiring an additional 312 shares during the quarter. LRI Investments LLC’s holdings in BioNTech were worth $47,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its position in BioNTech by 94.6% during the first quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company’s stock worth $108,859,000 after buying an additional 581,173 shares during the period. Aberdeen Group plc increased its position in BioNTech by 87.2% during the second quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock worth $76,864,000 after buying an additional 336,260 shares during the period. Bank of New York Mellon Corp increased its position in BioNTech by 18,892.9% during the first quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company’s stock worth $63,593,000 after buying an additional 694,691 shares during the period. Invesco Ltd. grew its stake in shares of BioNTech by 643.7% in the 1st quarter. Invesco Ltd. now owns 645,142 shares of the company’s stock valued at $58,747,000 after purchasing an additional 558,389 shares during the last quarter. Finally, Millennium Management LLC grew its stake in shares of BioNTech by 252.5% in the 1st quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock valued at $49,625,000 after purchasing an additional 390,360 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Performance

BNTX opened at $102.30 on Tuesday. The firm has a market cap of $24.59 billion, a PE ratio of -63.94 and a beta of 1.45. The business has a fifty day simple moving average of $104.32 and a 200-day simple moving average of $103.68. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a fifty-two week low of $81.20 and a fifty-two week high of $129.27.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. During the same period in the previous year, the business posted ($3.36) EPS. BioNTech’s revenue for the quarter was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. As a group, equities analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. JPMorgan Chase & Co. lifted their target price on BioNTech from $116.00 to $121.00 and gave the company a “neutral” rating in a research note on Monday, September 22nd. Bank of America boosted their target price on BioNTech from $126.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Wells Fargo & Company set a $150.00 target price on shares of BioNTech and gave the company an “overweight” rating in a research note on Tuesday, August 5th. Morgan Stanley cut their price target on BioNTech from $133.00 to $131.00 and set an “overweight” rating for the company in a report on Friday. Finally, HC Wainwright reiterated a “buy” rating and issued a $136.00 target price on shares of BioNTech in a research note on Monday, September 8th. Ten research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $134.32.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.